How do Globalstar, Inc. and Innoviva, Inc. compare by revenue?

Globalstar, Inc. reported revenue of $72.0M in Q4 FY2025, while Innoviva, Inc. reported $114.6M in Q4 FY2025. Innoviva, Inc. is 1.6× larger by last-quarter revenue.

Which is growing revenue faster, Globalstar, Inc. or Innoviva, Inc.?

Globalstar, Inc.'s latest revenue grew 17.6% year-over-year, versus 24.8% for Innoviva, Inc.. Innoviva, Inc. is growing faster on a YoY basis.

Which has a higher net margin, Globalstar, Inc. or Innoviva, Inc.?

Globalstar, Inc.'s net margin is -16.1% vs Innoviva, Inc.'s 143.2%. Innoviva, Inc. has the higher bottom-line margin.

What is the 2-year revenue CAGR for Globalstar, Inc. vs Innoviva, Inc.?

Over the trailing 8 quarters, Globalstar, Inc. compounded revenue at roughly 12.9% per year, versus 21.6% for Innoviva, Inc.. Innoviva, Inc. has the faster medium-term growth trajectory.

Where does this GSAT vs INVA data come from?

All figures are parsed directly from SEC EDGAR 10-Q / 10-K / 20-F / 6-K filings (for US-listed issuers) or EDINET filings (for Japanese issuers), then normalised into a common schema. Numbers update automatically as new filings are released.

vs

Side-by-side financial comparison of Globalstar, Inc. (GSAT) and Innoviva, Inc. (INVA). Click either name above to swap in a different company.

Innoviva, Inc. is the larger business by last-quarter revenue ($114.6M vs $72.0M, roughly 1.6× Globalstar, Inc.). Innoviva, Inc. runs the higher net margin — 143.2% vs -16.1%, a 159.4% gap on every dollar of revenue. On growth, Innoviva, Inc. posted the faster year-over-year revenue change (24.8% vs 17.6%). Over the past eight quarters, Innoviva, Inc.'s revenue compounded faster (21.6% CAGR vs 12.9%).

Globalstar, Inc.GSATEarnings & Financial Report

Nasdaq · Communication Services · Communications Services, NEC

Globalstar, Inc. is an American telecommunications company that operates a satellite constellation in low Earth orbit (LEO) for satellite phone, low-speed data transmission and Earth observation. The Globalstar second-generation constellation consists of 25 satellites.

Innoviva, Inc.INVAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Innoviva, Inc. is a healthcare company specializing in the development, commercialization, and royalty management of prescription therapeutics for respiratory diseases, infectious diseases, and critical care conditions. It partners with leading global pharmaceutical firms to deliver treatments for asthma, COPD and other chronic illnesses to patients across core markets including North America and Europe.

GSAT vs INVA — Head-to-Head

Bigger by revenue

INVA

1.6× larger

$114.6M

$72.0M

Growing faster (revenue YoY)

INVA

+7.2% gap

24.8%

17.6%

Higher net margin

INVA

159.4% more per $

143.2%

-16.1%

Faster 2-yr revenue CAGR

INVA

Annualised

21.6%

12.9%

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric	GSAT	INVA
Revenue	$72.0M	$114.6M
Net Profit	$-11.6M	$164.2M
Gross Margin	—	66.0%
Operating Margin	-0.5%	34.0%
Net Margin	-16.1%	143.2%
Revenue YoY	17.6%	24.8%
Net Profit YoY	76.9%	707.4%
EPS (diluted)	$-0.11	$2.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue

GSAT

INVA

Q4 25	$72.0M	$114.6M
Q3 25	$73.8M	$107.8M
Q2 25	$67.1M	$100.3M
Q1 25	$60.0M	$88.6M
Q4 24	$61.2M	$91.8M
Q3 24	$72.3M	$89.5M
Q2 24	$60.4M	$99.9M
Q1 24	$56.5M	$77.5M

Net Profit

GSAT

INVA

Q4 25	$-11.6M	$164.2M
Q3 25	$1.1M	$89.9M
Q2 25	$19.2M	$63.7M
Q1 25	$-17.3M	$-46.6M
Q4 24	$-50.2M	$20.3M
Q3 24	$9.9M	$1.2M
Q2 24	$-9.7M	$-34.7M
Q1 24	$-13.2M	$36.5M

Gross Margin

GSAT

INVA

Q4 25	—	66.0%
Q3 25	—	70.1%
Q2 25	—	82.9%
Q1 25	—	82.7%
Q4 24	—	85.1%
Q3 24	—	81.6%
Q2 24	—	85.1%
Q1 24	—	77.5%

Operating Margin

GSAT

INVA

Q4 25	-0.5%	34.0%
Q3 25	13.8%	32.1%
Q2 25	9.2%	48.6%
Q1 25	-14.2%	46.7%
Q4 24	-6.9%	47.0%
Q3 24	13.0%	48.3%
Q2 24	-2.4%	54.7%
Q1 24	-8.3%	33.3%

Net Margin

GSAT

INVA

Q4 25	-16.1%	143.2%
Q3 25	1.5%	83.4%
Q2 25	28.6%	63.5%
Q1 25	-28.9%	-52.6%
Q4 24	-82.1%	22.1%
Q3 24	13.7%	1.4%
Q2 24	-16.0%	-34.7%
Q1 24	-23.4%	47.1%

EPS (diluted)

GSAT

INVA

Q4 25	$-0.11	$2.19
Q3 25	$-0.01	$1.08
Q2 25	$0.13	$0.77
Q1 25	$-0.16	$-0.74
Q4 24	$-0.57	$0.43
Q3 24	$0.00	$0.02
Q2 24	$-0.01	$-0.55
Q1 24	$-0.01	$0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric	GSAT	INVA
Cash + ST InvestmentsLiquidity on hand	$447.5M	$550.9M
Total DebtLower is stronger	$483.8M	—
Stockholders' EquityBook value	$355.7M	$1.2B
Total Assets	$2.3B	$1.6B
Debt / EquityLower = less leverage	1.36×	—

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments

GSAT

INVA

Q4 25	$447.5M	$550.9M
Q3 25	$346.3M	$476.5M
Q2 25	$308.2M	$397.5M
Q1 25	$241.4M	$319.1M
Q4 24	$391.2M	$305.0M
Q3 24	$51.9M	$260.6M
Q2 24	$64.3M	$217.0M
Q1 24	$59.3M	$178.4M

Total Debt

GSAT

INVA

Q4 25	$483.8M	—
Q3 25	$508.6M	—
Q2 25	$491.5M	—
Q1 25	$502.7M	—
Q4 24	$511.4M	—
Q3 24	$394.4M	—
Q2 24	$393.1M	—
Q1 24	$398.7M	—

Stockholders' Equity

GSAT

INVA

Q4 25	$355.7M	$1.2B
Q3 25	$364.8M	$1.0B
Q2 25	$360.9M	$714.8M
Q1 25	$344.3M	$646.9M
Q4 24	$358.9M	$691.2M
Q3 24	$394.1M	$668.5M
Q2 24	$383.0M	$665.5M
Q1 24	$377.1M	$703.7M

Total Assets

GSAT

INVA

Q4 25	$2.3B	$1.6B
Q3 25	$2.2B	$1.4B
Q2 25	$1.9B	$1.3B
Q1 25	$1.7B	$1.3B
Q4 24	$1.7B	$1.3B
Q3 24	$917.6M	$1.2B
Q2 24	$926.2M	$1.2B
Q1 24	$917.0M	$1.3B

Debt / Equity

GSAT

INVA

Q4 25	1.36×	—
Q3 25	1.39×	—
Q2 25	1.36×	—
Q1 25	1.46×	—
Q4 24	1.43×	—
Q3 24	1.00×	—
Q2 24	1.03×	—
Q1 24	1.06×	—

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric	GSAT	INVA
Operating Cash FlowLast quarter	$175.9M	$54.5M
Free Cash FlowOCF − Capex	—	—
FCF MarginFCF / Revenue	—	—
Capex IntensityCapex / Revenue	—	—
Cash ConversionOCF / Net Profit	—	0.33×
TTM Free Cash FlowTrailing 4 quarters	—	—